71 related articles for article (PubMed ID: 22766771)
1. Food for thought: Souvenaid in mild Alzheimer’s disease.
Cummings JL
J Alzheimers Dis; 2012; 31(1):237-8. PubMed ID: 22766771
[No Abstract] [Full Text] [Related]
2. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial.
Scheltens P; Twisk JW; Blesa R; Scarpini E; von Arnim CA; Bongers A; Harrison J; Swinkels SH; Stam CJ; de Waal H; Wurtman RJ; Wieggers RL; Vellas B; Kamphuis PJ
J Alzheimers Dis; 2012; 31(1):225-36. PubMed ID: 22766770
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial.
Scheltens P; Kamphuis PJ; Verhey FR; Olde Rikkert MG; Wurtman RJ; Wilkinson D; Twisk JW; Kurz A
Alzheimers Dement; 2010 Jan; 6(1):1-10.e1. PubMed ID: 20129316
[TBL] [Abstract][Full Text] [Related]
4. Effect Size Analyses of Souvenaid in Patients with Alzheimer's Disease.
Cummings J; Scheltens P; McKeith I; Blesa R; Harrison JE; Bertolucci PH; Rockwood K; Wilkinson D; Wijker W; Bennett DA; Shah RC
J Alzheimers Dis; 2017; 55(3):1131-1139. PubMed ID: 27767993
[TBL] [Abstract][Full Text] [Related]
5. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
Chiu CC; Su KP; Cheng TC; Liu HC; Chang CJ; Dewey ME; Stewart R; Huang SY
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1538-44. PubMed ID: 18573585
[TBL] [Abstract][Full Text] [Related]
6. The clinical utility of the Mattis Dementia Rating Scale in assessing cognitive decline in Alzheimer's disease.
Miller JM; Pliskin NH
Int J Neurosci; 2006 May; 116(5):613-27. PubMed ID: 16644521
[TBL] [Abstract][Full Text] [Related]
7. Galantamine for Alzheimer's disease and mild cognitive impairment.
Cusi C; Cantisani TA; Celani MG; Incorvaia B; Righetti E; Candelise L;
Neuroepidemiology; 2007; 28(2):116-7. PubMed ID: 17409773
[No Abstract] [Full Text] [Related]
8. Working memory in mild cognitive impairment and Alzheimer's disease: contribution of forgetting and predictive value of complex span tasks.
Gagnon LG; Belleville S
Neuropsychology; 2011 Mar; 25(2):226-36. PubMed ID: 21090897
[TBL] [Abstract][Full Text] [Related]
9. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
[TBL] [Abstract][Full Text] [Related]
10. Souvenaid®: a new approach to management of early Alzheimer's disease.
Ritchie CW; Bajwa J; Coleman G; Hope K; Jones RW; Lawton M; Marven M; Passmore P
J Nutr Health Aging; 2014 Mar; 18(3):291-9. PubMed ID: 24626757
[TBL] [Abstract][Full Text] [Related]
11. A neuropsychological test battery for use in Alzheimer disease clinical trials.
Harrison J; Minassian SL; Jenkins L; Black RS; Koller M; Grundman M
Arch Neurol; 2007 Sep; 64(9):1323-9. PubMed ID: 17846273
[TBL] [Abstract][Full Text] [Related]
12. [Early diagnosis of Alzheimer's disease: the prodromal and preclinical phase].
Valls-Pedret C; Molinuevo JL; Rami L
Rev Neurol; 2010 Oct; 51(8):471-80. PubMed ID: 20925029
[TBL] [Abstract][Full Text] [Related]
13. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
Frölich L; Ashwood T; Nilsson J; Eckerwall G;
J Alzheimers Dis; 2011; 24(2):363-74. PubMed ID: 21258153
[TBL] [Abstract][Full Text] [Related]
14. Different cognitive profiles between mild cognitive impairment due to cerebral small vessel disease and mild cognitive impairment of Alzheimer's disease origin.
Zhou A; Jia J
J Int Neuropsychol Soc; 2009 Nov; 15(6):898-905. PubMed ID: 19891819
[TBL] [Abstract][Full Text] [Related]
15. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
Jenike MA; Albert MS; Heller H; Gunther J; Goff D
J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
[TBL] [Abstract][Full Text] [Related]
16. The need for a consensus in the use of assessment tools for Alzheimer's disease: the Feasibility Study (assessment tools for dementia in Alzheimer Centres across Europe), a European Alzheimer's Disease Consortium's (EADC) survey.
Paulino Ramirez Diaz S; Gil Gregório P; Manuel Ribera Casado J; Reynish E; Jean Ousset P; Vellas B; Salmon E
Int J Geriatr Psychiatry; 2005 Aug; 20(8):744-8. PubMed ID: 16035121
[TBL] [Abstract][Full Text] [Related]
17. [Discriminant capacity of neuropsychological efficiency in the Alzheimer's disease].
López-Pousa S; Garre-Olmo J
Rev Neurol; 2000 Sep 16-30; 31(6):534-5. PubMed ID: 11055056
[No Abstract] [Full Text] [Related]
18. [Scales used for therapeutic trials in Alzheimer's disease].
Vercelletto M
Rev Neurol (Paris); 2002 Sep; 158(8-9):857-61. PubMed ID: 12386538
[No Abstract] [Full Text] [Related]
19. Anosognosia in Alzheimer's disease: association with patient characteristics, psychiatric symptoms and cognitive deficits.
Kashiwa Y; Kitabayashi Y; Narumoto J; Nakamura K; Ueda H; Fukui K
Psychiatry Clin Neurosci; 2005 Dec; 59(6):697-704. PubMed ID: 16401246
[TBL] [Abstract][Full Text] [Related]
20. Does rivastigmine improve cognitive functions or disability in patients with Alzheimer's disease?
Cantisani TA; Celani MG; Righetti E
Neuroepidemiology; 2004; 23(4):209-10. PubMed ID: 15272224
[No Abstract] [Full Text] [Related]
[Next] [New Search]
